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donverging Pharmacological and Genetic Evidence
ndicates a Role for Steroid Sulfatase in Attention
illiam Davies, Trevor Humby, Wendy Kong, Tamara Otter, Paul S. Burgoyne, and
awrence S. Wilkinson
ackground: Attention-deficit/hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder characterized by deficits in
ttention, increasedmotor impulsivity, andhyperactivity. Preliminarywork inmice andhumans has suggested theX-linkedgene STS (which
ncodes the enzyme steroid sulfatase) as a mediator of attentional functioning and as a candidate gene for ADHD.
ethods: The effects of modulating the murine steroid sulfatase axis pharmacologically (through administration of the substrate dehy-
roepiandrosterone sulfate [DHEAS], 0–40mg/kg, or acute inhibition of the enzyme by COUMATE, 10mg/kg) or genetically (through loss of
he gene in 39,XY*O mice) were assayed using the 5-choice serial reaction time task (5-CSRTT) a test of visuospatial attention and response
ontrol, and a locomotor activity paradigm.
esults: DHEAS administration improved 5-CSRTT performance under attentionally demanding conditions, whereas steroid sulfatase
nhibition impaired accuracy under the same conditions. Loss of Sts expression constitutively throughout development in 39,XY*O mice
esulted indeficits in 5-CSRTTperformanceat short stimulusdurations and reducedanticipatory responding.Neither thepharmacologic nor
he genetic manipulations affected basic locomotor activity.
onclusions: These data provide converging evidence indicating a role for steroid sulfatase in discrete aspects of attentional functioning
nd are suggestive of a role inmotor impulsivity. The findings provide novel insights into the neurobiology of attention and strengthen the
otion of STS as a candidate gene for the attentional component of ADHD.ey Words: Accuracy, attention-deficit/hyperactivity disorder, de-
ydroepiandrosterone sulfate, 5-choice serial reaction time task,
urner syndrome, X chromosome
ttention-deficit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental disorder characterized by deficits in
attention, hyperactivity, and increased motor impulsivity
1). Although environmental factors may play a role in precipi-
ating the disorder (2), there is also a strong underlying genetic
omponent (3). Diagnosis of ADHD is approximately 4 times
ore common in males than in females (4), and the etiology of
he disorder is sex-specific (5–7); therefore, genes on the sex
hromosomes may influence susceptibility.
Evidence for an X-linked gene influencing attention has come
rom work in Turner syndrome (TS) subjects. Individuals with TS
re females who, most typically, lack a whole X chromosome.
hey are impaired on neuropsychological and real-life tests of
ttention (8–10) and are at increased ADHD risk relative to 46,XX
ubjects (11). We have previously shown that female mice with
single X chromosome (39,XO) also show attentional deficits
elative to their 40,XX litter mates (12). Additionally, we showed
hat 40,XY*X mice (essentially 39,XO mice bearing a small
umber of extra genes on the Y*X chromosome) do not differ
rom 40,XX mice in terms of their attentional performance,
mplying that Y*X genes can influence attention. We argued that
rom the Behavioural Genetics Group (WD, TH, TO, LSW), School of Psychol-
ogy and Department of Psychological Medicine, School of Medicine,
University of Cardiff; Department of Anatomy (WK), University of Bristol;
and Division of Stem Cell Biology and Developmental Genetics (PSB),
Medical Research Council National Institute for Medical Research, Lon-
don, United Kingdom.
ddress correspondence toWilliamDavies, Ph.D., HenryWellcomeBuilding,
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oi:10.1016/j.biopsych.2009.01.001Sts, encoding the enzyme steroid sulfatase, represents the best
candidate for this “rescue” effect on the basis of its expression
pattern and function (12). In humans, as in mouse, STS escapes
X-inactivation (13); thus, it may be regarded as a candidate gene
for the TS attentional deficits.
Steroid sulfatase converts various sulfated compounds to their
nonsulfated forms, notably the neurosteroid dehydroepiandros-
terone sulfate (DHEAS) to DHEA (14); DHEAS and DHEA have
important effects on neural function, including cognition (15). In
the mouse brain, Sts is most highly expressed in the cortex,
hindbrain, and thalamus, with lower expression elsewhere (16).
Levels peak around the perinatal period and are relatively low
thereafter (17). In humans, STS is expressed in the neocortex
(18). Steroid sulfatase influences the malignancy of hormone-
dependent cancers (probably by enhancing the availability of
free steroid precursors). Consequently, substantial effort has
been invested in developing specific inhibitors of the enzyme
for therapy, for example, the arylsulfamate-based compound
COUMATE (19,20). In mice, systemic COUMATE administration
results in profound attenuation ( 70%) of brain steroid sulfatase
activity within 24 hours (21).
Previous data have implicated STS in ADHD risk: males with
cytogenetic deletions encompassing the gene (or with inactivat-
ing mutations within it) appear to show an enhanced vulnera-
bility to the disorder (22–25). However, the pleiotropic effects of
multiple gene deletions, the small sample sizes used, and the
lack of appropriate control samples means that the conclusions
of these studies should be interpreted cautiously. We directly
tested the hypothesis that steroid sulfatase could influence
ADHD endophenotypes (attention, motor impulsivity, and activ-
ity) using mouse models. Two approaches were employed: in a
pharmacologic approach, adult mice were given DHEAS or
COUMATE to ascertain the effects of acute manipulation of the
steroid sulfatase axis. Because ADHD can persist into adulthood
with adverse consequences (26), such an approach could shed
light on the molecular pathogenesis of adult ADHD. In a parallel
BIOL PSYCHIATRY 2009;66:360–367
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W. Davies et al. BIOL PSYCHIATRY 2009;66:360–367 361enetic approach, 39,XY*O male mice (27) were compared with
0,XY males. 39,XY*O mice have a single large sex chromosome
omprising the X and Y attached via an end-to-end fusion of their
seudoautosomal regions, with both copies of the Sts gene
eleted but a normal complement of all other X and Y genes (28)
Figure 1). Using this model, the effects of loss of steroid sulfatase
unction throughout development could be determined.
Attention was assayed using the 5-choice serial reaction time
ask (5-CSRTT) (29) in which subjects must respond as accurately
nd as rapidly as possible with a directed nose-poke response to
he presentation of a light stimulus presented pseudo-randomly
n one of five spatial locations to gain a reinforcer. This task also
rovides an index of motor impulsivity in that it is possible to
easure the ability of the subjects to withhold responding in a
ause (the “intertrial interval”) before the onset of the stimulus.
he neural substrates underlying 5-CSRTT performance have
een well specified in rodents (30).
On the basis of our previous findings (12), the main predic-
ion at the outset of the experiments was that pharmacologic or
enetic manipulations (or both) influencing the steroid sulfatase
xis would result in alterations in attention.
ethods andMaterials
ubjects
For the pharmacologic study, we used male MF1 mice (Har-
an, Bicester, United Kingdom). Behavioral testing commenced
t approximately 5 months of age. For the genetic study, 40,XY
nd 39,XY*O male mice on identical genetic backgrounds were
mported from Medical Research Council National Institute for
edical Research, United Kingdom. 39,XY*O mice were pro-
uced from two separate crosses: 39,XPafO x 40,XY* and
9,XPafO x 39,XY*O (see Supplement 1). Behavioral testing
ommenced at 4–6 months of age. Mice were treated in accor-
ance with the Animal Scientific Procedures Act (United King-
om, 1986). For details of animal husbandry, see Supplement 1.
einforcer Preference, 5-CSRTT Training to Stable Baseline
erformance
Reinforcer preference was carried out as described previously
29), with the main index of preference being the amount of
einforcer (10% condensed milk solution, Nestle, Croydon,
igure 1. In 39,XY*Omice, an end-to-end fusion of the X and Y chromosome
seudo-autosomal regions results in deletion of both copies of the Stsgene.nited Kingdom) drunk on the final day of preference testing asa percentage of total fluid consumption (choice between water
and reinforcer). The 5-CSRTT apparatus, behavioral shaping, trial
design, and training are described in detail elsewhere (12) (see
also Supplement 1). At baseline stimulus durations of 1 sec, mice
performed more than 50 trials at greater than 80% accuracy (i.e.,
correct:incorrect responses) and less than 30% omissions (i.e., no
response to stimulus presentation); the intertrial interval (ITI)
was set to 5 sec.
5-CSRTTManipulations
At stable baseline performance (baseline criteria for  5
consecutive days), three behavioral manipulations designed to
affect different aspects of attentional load/impulse control were
performed with 2 or more days of consecutive baseline perfor-
mance between each manipulation session: 1) short stimulus
durations (.25, .5, .75 and 1.0 sec), 2) extra-short stimulus
durations (.1, .3, .5, and .7 sec; short stimulus durations increas-
ing attentional load), and 3) long ITI (5, 6, 7, and 8 sec; long ITIs
taxing the ability to withhold responding). During manipulation
sessions, the various parameters were presented pseudo-ran-
domly. Where relevant, following completion of these manipu-
lation sessions in the 5-CSRTT, the extent to which any effects on
behavior could be attributed to attentional processes was further
assessed in a 1-choice version of the task (1-CSRTT) in which
attentional demands of the task were reduced by only presenting
the stimulus in the central response hole (12,29). Stimulus
duration manipulations were performed after five or more ses-
sions at criterion on the modified task.
Behavioural Measures on the 5-CSRTT/1-CSRTT
The following behavioral measures were recorded: number of
trials, accuracy and omissions, (indexing failures of detection
and/or motivational/motor deficits) (30), number of premature
responses (i.e., nose pokes made in the ITI before stimulus
presentation, indexing motor impulsivity) (30), correct response
latency (defined as the time taken to nose poke in the illuminated
hole following stimulus onset), and the latency to collect and
consume the reinforcer.
Pharmacological Analysis in the 5-CSRTT/1-CSRTT
In the first part of the pharmacologic study, DHEAS (Sigma-
Aldrich, Gillingham, United Kingdom) was administered to mice
(n  12) at stable baseline performance on the 5-CSRTT 1 hour
before behavioral testing. Each mouse received four doses of
drug (0, 5, 15, and 40 mg/kg in distilled water intraperitoneal
[i.p.]) with at least 72 hours washout between treatments; the
order in which the doses were given was pseudo-randomized to
negate possible order effects. The drug doses selected have
previously been shown to influence behavior in mice (21,31).
Subsequently, each mouse was given either vehicle or 40 mg/kg
DHEAS (pseudo-randomized) and tested specifically on the
5-CSRTT short-stimulus-duration manipulation; following wash-
out, mice were given the opposite drug/vehicle treatment and
retested on the task manipulation. In the second part of the
study, mice (n  12) were pseudo-randomly injected either with
vehicle (.5% methylcellulose, .9% NaCl in distilled water per os
[p.o.]) or with COUMATE (10 mg/kg in the same vehicle p.o.,
COUMATE made according to [21]) 24 hours before behavioral
testing on the short-stimulus-duration manipulation in the 5-CS-
RTT. After at least 72 hours washout, mice were given the
opposite drug/vehicle treatment and retested. The effects of
COUMATE administration were then tested in the 1-CSRTT under
the same conditions.
www.sobp.org/journal
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wocomotor Activity
Locomotor activity was measured in dim lighting (5 lux) using
ages each fitted with two infrared beams. Mice were allowed to
xplore freely for a 1-hour session, with the number of individual
nfrared beam breaks indexing their activity. For the pharmaco-
ogic study, mice (n  7) were run for 6 days (1 session per day)
o habituate them to the apparatus and to limit any interactions
etween drug treatment and reactivity to novelty. They were
hen treated with either vehicle or COUMATE 24 hours before
esting. After washout, the mice were given the opposite treat-
ent and rerun. The 40,XY (n  20) and 39,XY*O (n  14) mice
ere run on 3 consecutive days to ascertain the effects of Sts loss
n reactivity to a novel environment and basic locomotor
ctivity.
tatistical Analysis
Statistical analysis was performed using SPSS12. Data were
ubject to t test or repeated-measures analysis of variance
ANOVA) if normal, with factors Drug Treatment/Genotype
nd Task Manipulation/Day or Mann-Whitney U test and
ilcoxon Signed-Ranks test (if not normal). t tests, Mann-
hitney U tests, and Wilcoxon Signed-Ranks tests were used
o analyze overall performance in the task. Percentage data
accuracy and omissions) and premature response data were
rcsine or square root transformed, respectively, before
NOVA (32). If ANOVA indicated a significant interaction
etween factors, post hoc pairwise comparisons were per-
ormed using Tukey’s honestly significant difference test.
alues of p  .05 were regarded as significant. The results
ere not corrected for multiple testing. Data are presented as
ean values  standard error of the mean.
esults
harmacologic Study
DHEAS Does Not Influence Baseline Performance in the
-CSRTT. DHEAS administration at any of the doses tested didww.sobp.org/journalnot significantly affect the main 5-CSRTT performance measures
at baseline (Supplement 1).
DHEASReducesOmissionsUnder Attentionally Demanding
Conditions. We tested whether the highest dose of DHEAS (40
mg/kg) would influence behavior under more attentionally de-
manding conditions (i.e., attenuated stimulus durations). As at
baseline, DHEAS administration did not affect trial number [Drug
Treatment, t (11)  .58, ns, Figure 2A], nor did it influence
accuracy [Drug Treatment, F(1,11)  .03, ns, Drug Treatment 
Task Manipulation, F(3,33) .82, ns, Figure 2B]. However, DHEAS
treatment did appear to enhance task performance specifically at
the shortest stimulus duration of .25 sec, as reflected in the signifi-
cant Drug Treatment Task Manipulation interaction on omissions
[F(3,33)  3.23, p  .035] and subsequent post hoc test (p  .05;
Figure 2C). DHEAS did not affect correct response latency under the
shorter stimulus conditions [Drug Treatment, F(1,11)  .76, ns,
Drug Treatment Task Manipulation, F(3,33) .25, ns, Figure 2D],
nor the total number of premature responses made [Drug Treat-
ment, t (11)  1.34, ns].
COUMATE Impairs Accuracy in the 5-CSRTT Under Atten-
tionally Demanding Conditions; This Impairment Is Alleviated
in the 1-CSRTT. COUMATE administration resulted in signifi-
cantly decreased accuracy under short-stimulus-duration condi-
tions [Drug Treatment, F (1,11)  8.87, p  .013]; this deficit in
accuracy was particularly pronounced at the shortest .25-sec
stimulus duration [Drug Treatment Task Manipulation, F(3,33)
3.79, p  .019, subsequent pairwise comparison p  .01; Figure
3B]. The effects of the drug manipulation were behaviorally
specific in that there were no effects of Drug Treatment on trial
number [t (11)1.34, ns, Figure 3A), omissions [F (1,11) .01,
ns, Drug Treatment  Task Manipulation, F (3,33)  1.47, ns,
Figure 3C], correct response latency [F (1,11)  .14, ns, Drug
Treatment  Task Manipulation, F (3,33)  .11, ns, Figure 3D] or
total number of premature responses (Vehicle vs. COUMATE,
3.2  1.0 vs. 5.2  1.6, W  27, Z  1.33, ns). Furthermore,
Drug Treatment did not influence two measures of motivation:
the latency to collect and consume the reinforcer [F (1,11)  .18,
Figure 2. Effects of dehydroepiandrosterone sulfate
(DHEAS) administration on behavioral indices of atten-
tion during a 5-choice serial reaction time task manip-
ulation in which stimulus durations were reduced. The
drug treatment did not significantly affect the number
of trials performed (A) or accuracy at any value of
stimulus duration (B). However, DHEAS did result in
fewer omissions at the shortest, and therefore, most
attentionally demanding, time point (*p  .05) (C).
There were no significant effects of the treatment on
the latency taken tomake at correct choice at any value
of stimulus duration (D).
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Baseline performance on the 1-CSRTT was, as expected,
uperior to that on the 5-CSRTT (accuracy:  95%, omissions: 
5%, correct response latency: .85 sec). In the 1-CSRTT,
OUMATE did not affect accuracy [Drug Treatment, F (1,11) 
02, ns; Drug Treatment  Task Manipulation, F (3,33)  .89, ns;
igure 3E]. There were no effects of Drug Treatment on omis-
ions [F (1,11)  .00, ns, and Drug Treatment  Task Manipula-
ion, F (3,33) .70, ns] or correct response latency [F (1,11) .89,
s, Drug Treatment  Task Manipulation, F (3,33)  .56, ns].
enetic Study
40,XY and39,XY*OMiceDemonstrate Equivalent Reinforcer
reference, 5-CSRTT Acquisition, and Baseline Performance.
he 40,XY (n  9) and 39,XY*O (n  12) mice were trained to
erformance criteria in the 5-CSRTT. The groups displayed
quivalent reinforcer preference [78.8  5.5% vs. 84.7  4.8%,
espectively, GENOTYPE, t (19)  .81, ns] and acquired the
ask in an equal number of sessions, indicating no effects of
enotype on learning [68.4  8.1 vs. 63.6  8.8, respectively,
(19)  .39, ns]. At baseline, 40,XY and 39,XY*O mice generally
erformed equivalently (Table 1), although the 39,XY*O mice
dopted a more efficient response strategy, performing fewer
ose pokes per trial than 40,XY subjects.
39,XY*O Mice Show Increased Omissions Relative to 40,XY
ice Under Attentionally Demanding Conditions; This Group
ifference Is Abolished in the 1-CSRTT. To further tax attention,
e compared the performance of 40,XY and 39,XY*O mice on
wo manipulations in which stimulus durations were attenuated:
ne with stimulus durations ranging from 1.0 to .25 sec and a
igure 3. Effects of steroid sulfatase inhibition by COUMATE administration
eaction time task (1-CSRTT) manipulations in which stimulus durations wer
he 5-CSRTT (A) but did have significant effects on accuracy (B); this drug
ttentionally demanding stimulus duration of .25 sec (**p  .01). The dru
D). Importantly, when the attentional demands of the task were reduced inecond, more attentionally demanding manipulation, with stim-ulus durations ranging from .7 to .1 s. On the first manipulation,
there was no effect of Genotype with respect to the two main
indices of attention, accuracy and omissions [F (1,19)  .31, ns,
and F (1,19)  .00, ns, respectively], although there was a trend
for 39,XY*O mice to make more omissions than 40,XY mice at the
shortest stimulus duration (Genotype  Task Manipulation,
F (3,57)  1.54, ns]. On the second manipulation, this effect on
omissions was more pronounced, giving rise to a significant
Genotype  Task Manipulation interaction F (3,57)  4.53, p 
.01] and a significant pairwise comparison at the shortest stimulus
duration of .1 sec (p  .01; Figure 4C). Importantly, this effect
occurred in the absence of any Genotype effects on markers of
motivation including trial number [t (19)  1.07, ns, Figure 4A],
ehavioral indices of attention during 5-choice (5-CSRTT) and 1-choice serial
uced. The drug treatment did not affect total number of trials performed in
t was present at all stimulus durations but was most marked at the most
nipulation had no effects on omissions (C) or correct response latencies
-CSRTT, COUMATE administration had no effect on accuracy (E).
Table 1. Baseline Performance on the 5-Choice Serial Reaction Time Task
Behavioral Parameter
40,XY
(n 9)
39,XY*O
(n 12) Effect of Genotype
Number of Trials 74.5 4.1 83.7  3.7 t(19)  1.61, ns
Accuracy (%) 93.3 1.3 95.2  .8 t(19)  1.18, ns
Omissions (%) 15.1 1.4 15.8  1.2 t(19)  .38, ns
Correct Response
Latency (sec)
.85  .06 .91  .04 t(19)  .85, ns
Latency to Collect
Reinforcer (sec)
3.33  .86 2.84  .59 t(19)  .49, ns
Latency to Consume
Reinforcer (sec)
1.98  .49 2.00  .41 t(19)  .03, ns
Premature Responses 2.1 .5 1.3  .3 U  54, ns
Nose Pokes Per Trial 1.33 .16 1.02  .04 t(19)  2.18, p  .04on b
e red
effec
g maPanel Pushes Per Trial 1.90 .14 1.79  .17 t(19)  .48, ns
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worrect response latency [F (1,19)  .43, ns, Genotype  Task
anipulation, F (3,57) .45, ns, Figure 4D], latency to collect the
einforcer [F (1,19)  1.39, ns, Genotype  Task Manipulation,
(3,57)  1.38, ns], and latency to consume the reinforcer
F (1,19)  1.46, ns, Genotype  Task Manipulation, F (3,57) 
.02, ns]. Although accuracy did not differ significantly between
enotypes on this latter manipulation [Genotype, F (1,19)  .02,
s], there was a trend toward impaired performance in the
9,XY*O group at the shortest stimulus duration of .1 s [Genotype
ask Manipulation, F(3,57)  1.71, ns, Figure 4B].
Baseline performance of 40,XY and 39,XY*O mice in the
-CSRTT was equivalent and superior to that in the 5-CSRTT
Table 2). In the 1-CSRTT, there were no stimulus duration-
ependent group effects on omissions [Genotype, F (1,19) 
igure 4. Effects of Sts gene loss in 39,XY*O mice on behavioral indices
1-CSRTT) manipulations in which stimulus durations were reduced. The
ame degree of accuracy (B). At the shortest stimulus duration, 39,XY*Om
anipulation were observed on correct response latencies for any valu
educed in the 1-CSRTT, 39,XY*O mice performed equivalently to 40,XY m
able 2. Baseline Performance on the 1-Choice Serial Reaction Time Task
ehavioral Parameter
40,XY
(n 9)
39,XY*O
(n 12)
Effect of
Genotype
umber of Trials 73.3  5.2 77.9  5.2 t(19).61, ns
ccuracy (%) 97.8  .7 98.3  .2 t(19).25, ns
missions (%) 8.9 1.8 11.1  1.2 t(19)1.02, ns
orrect Response
Latency (sec)
.64  .04 .76  .05 t(19)1.74, ns
atency to Collect
Reinforcer (sec)
3.57  1.26 3.36  .97 t(19) .13, ns
atency to Consume
Reinforcer (sec)
2.10  .63 1.96  .43 t(19) .19, ns
remature Responses 1.4 .5 1.7  .5 U 54, ns
ose Pokes Per Trial 1.62 .36 1.10  .03 t(19) 1.65, ns
anel Pushes Per Trial 1.62 .12 1.70  .16 t(19).36, ns
ww.sobp.org/journal3.15, ns; Genotype  Task Manipulation, F (3,57)  .97, ns,
Figure 4E]. Furthermore, accuracy did not differ significantly
between the groups on the 1-CSRTT short-stimulus-duration
manipulation [Genotype, F (1,19)  1.18, ns; Genotype  Task
Manipulation, F (3,57)  .13, ns]. However, 39,XY*O mice tended
to respond correctly more slowly for all values of stimulus
duration than 40,XY mice [Genotype, F (1,19)  5.66, p  .03,
Genotype  Task Manipulation, F (3,57)  1.47, ns]. The only
other significant effect of Genotype was in the “long ITI”
5-CSRTT manipulation. As expected, premature responding in-
creased with increased ITI length [Task Manipulation, F (3,57) 
6.92, p  .0005], but unexpectedly 39,XY*O mice made fewer
anticipatory responses than 40,XY mice for all values of ITI
[Genotype, F (1,19)  4.39, p  .05, Genotype  Task Manipu-
lation, F (3,57)  .32, ns, Figure 5] suggesting that the former
group display a reduced tendency for impulsive responding.
Steroid Sulfatase Manipulations Do Not Affect Locomotor
Activity. COUMATE treatment did not have any effect on
locomotor activity [Drug Treatment, t (6)  .8, ns, Figure 6A].
Initial activity levels of 40,XY and 39,XY*O mice were identical
and decreased equally across sessions [Genotype: F (1,32)  .45,
ns; Genotype  DAY: F (2,64)  1.85, ns, Figure 6B].
Discussion
Previous studies have suggested that the enzyme steroid
sulfatase, encoded by the X-linked gene STS, and a modulator of
neuroactive steroid activity (15), may play a role in attention
(12,23). We tested this idea using pharmacologic and genetic
approaches in mouse models.
ention during 5-choice (5-CSRTT) and 1-choice serial reaction time task
groups performed equal numbers of trials in the 5-CSRTT (A) and to the
mitted more trials than 40,XY mice (**p .01) (C). No effects of the gene
stimulus duration (D). When the attentional demands of the task were
n terms of omissions at the shortest stimulus duration (E).of att
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ice o
e ofWe hypothesized that haploinsufficiency for steroid sulfatase
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W. Davies et al. BIOL PSYCHIATRY 2009;66:360–367 365ould account for attentional deficits in 39,XO mice through
imiting the conversion of DHEAS to DHEA (12). Hence, we
xpected that DHEAS administration (which leads to a rise in
rain DHEAS and DHEA within 1 hour) (33) may act to improve
spects of attention. DHEAS administration did indeed improve
-CSRTT performance at the shortest stimulus duration. Whether
t is DHEAS or one of its downstream metabolites (e.g., DHEA or
ndrostenediol) that causes this effect remains to be clarified, but
his finding is consistent with work showing that DHEA augmen-
ation in schizophrenic patients improves sustained attention
34). Because methylphenidate treatment has been shown to
ncrease systemic DHEA levels in ADHD subjects (35), we
ropose that DHEA administration may also improve attentional
unction in ADHD.
We further anticipated that inhibition of steroid sulfatase
ould elicit deficits on the 5-CSRTT that recapitulated those seen
n the 39,XO mouse. Like 39,XO mice, COUMATE-treated mice
howed specific impairments in accuracy at short stimulus dura-
ions on the 5-CSRTT, and, as in 39,XO mice, these drug-induced
eficits were rescued in the less attentionally demanding 1-
SRTT. Together these findings suggest that steroid sulfatase
nfluences ongoing attentional processes. Moreover, the data
ndicate that steroid sulfatase plays a similar role in attention in
oth male (COUMATE-treated) and female (39,XO) mice.
The 39,XY*O mice, which lack steroid sulfatase expression
hroughout development, demonstrated impaired 5-CSRTT per-
ormance (significantly increased omissions and a nonsignificant
rend toward impaired accuracy at short stimulus durations)
elative to 40,XY control mice; these deficits were rescued in
he 1-CSRTT. As 39,XY*O mice performed equivalently to 40,XY
ice at longer stimulus durations, and because the two groups of
igure 5. Effects of Sts gene loss in 39,XY*O mice on an index of motor
mpulsivity (premature responses) on a 5-choice serial reaction time task
5-CSRTT) manipulation in which the intertrial interval (ITI) between trial
nitiation and stimulus presentation was extended. 39,XY*O mice made
ewer premature responses than 40,XYmice for all values of ITI.mice were equally motivated, these results may again reasonably
be interpreted as a specific impairment in attention. These data,
together with previous findings in other models, support the
conclusion that alterations in steroid sulfatase function can lead
to specific changes in performance on the 5-CSRTT and that
these changes are likely to reflect attentional effects. Future work
may assess the effects of DHEAS and COUMATE administration
in 39,XY*O mice on 5-CSRTT performance to determine the
extent to which the behavioral effects mediated by these com-
pounds are truly Sts-dependent.
We note the discrepancy between the measures influenced by
acute inhibition of steroid sulfatase in COUMATE-treated mice
and constitutive loss of the Sts gene in 39,XY*O mice (effects
on accuracy and omissions, respectively). Such a discrepancy
may arise because of enzyme inhibition via COUMATE causing
acute, and only partial, loss of function, whereas Sts deletion
causes complete loss of the enzyme throughout development.
Interestingly, a similar dissociation between the effects of acute
pharmacologic and genetic manipulations of the cholinergic axis
on accuracy and omissions has been described previously (36).
Although both accuracy and omissions may be regarded as
indices of attention, the precise relationship between the two
measures, and the extent to which they index common psychol-
ogy and neurobiology in rodents, is unclear.
We also tested whether steroid sulfatase influences other
ADHD endophenotypes. Pharmacologic manipulations of the
steroid sulfatase axis had no effect on motor impulsivity (as
indexed by the degree of anticipatory responding), whereas
constitutive loss of Sts in 39,XY*O mice resulted in both signifi-
cantly fewer nose pokes per trial and reduced premature re-
sponding. Because ADHD is characterized by increased motor
impulsivity and because the incidence of hyperactive-impulsive
type ADHD in Turner syndrome is elevated (11), these latter
results are surprising. The dissociation between acute drug
effects and Sts loss may reflect the differential effects of steroid
sulfatase on ongoing and developmental processes, respectively.
In terms of developmental effects, DHEA is known to influence
neurogenesis (37). The dissociable effects of steroid sulfatase
manipulations on attention and impulse control suggest that it
would be interesting to perform other assays of response inhibi-
tion (e.g., stop-signal or delayed reinforcement paradigms) (38,
39). Neither steroid sulfatase inhibition nor Sts loss resulted in
effects on locomotor activity. These data, in conjunction with
previous data showing an absence of effects of 40mg/kg DHEAS
on locomotor activity in mice (40), indicate that steroid sulfatase
is unlikely to influence neurobiological pathways underpinning
activity. ADHD is often comorbid with conduct disorder and
oppositional-defiant disorder, which are typified by heightened
aggression (41). In light of this, and bearing in mind that
coadmininstration of COUMATE and DHEAS has previously
been shown to increase aggression in mice (21), it was interest-
Figure6. Effects of acute inhibitionof steroid sulfataseby
COUMATE, or loss of the Sts gene in 39,XY*O mice, on
locomotor activity. COUMATE administration had no ef-
fect on locomotor activity (A). The 39,XY*O mice showed
equivalent levels of activity to 40,XY mice on being
placed in a novel environment, and both groups habitu-
ated to the environment equally over 3 consecutive days
of testing (B).www.sobp.org/journal
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wng to observe that 39,XY*O mice appeared more overtly aggres-
ive than their 40,XY counterparts.
The neurobiological substrates of the behavioral effects de-
cribed herein are unknown. Sts is expressed predominantly in
he thalamus, with lesser expression in the cortex and hindbrain
16). Structural or functional changes in one or more of these
rain regions, together with their associated circuitry, may un-
erlie the behavioral effects. We have compared the expression
f a number of candidate attentional genes in vehicle and
OUMATE-treated mouse frontal cortex and thalamus but have
ailed to find any significant differences between the two groups
o date (Supplement 1).
In rats, lesions of the dorsal anterior cingulate cortex
roduce specific deficits in accuracy that resemble those seen
n COUMATE-treated mice (32), whereas lesions of either the
ucleus basalis magnocellularis (42) or the pedunculopontine
egmental nucleus (PPTg) (43) produce a pattern of deficits
nalogous to that observed in 39,XY*O mice (increased omissions
nd reduced accuracy at short stimulus durations and reduced
remature responding). In rodents, the basal forebrain cholin-
rgic complex (which includes the nucleus basalis magnocellu-
aris) projects directly to the cortex and hippocampus and also to
he thalamus, whereas the pontine cholinergic system exerts its
nfluence mainly through intralaminar thalamic nuclei, but it also
onnects to the basal forebrain and provides a minor innervation
f the cortex (44). Hence, our behavioral findings, in combina-
ion with previous data indicating links between steroid sulfatase
nd neurosteroid action on cholinergic systems (45–48), suggest
hat these manipulations may affect attentional functioning by
nfluencing cholinergic transmission (49,50).
A modulatory role for the steroid sulfatase axis on attention
hrough -aminobutyric acid(GABA)-ergic function is also pos-
ible: DHEAS is a known negative allosteric modulator of
ABAA-receptor-gated chloride channels (51), and Sts expres-
ion correlates with the expression of certain GABAA receptor
ubunits (52). Infusion of the GABAA receptor agonist muscimol
nto the subthalamic nucleus in rats (a site of Sts expression)
roduces an array of deficits recapitulating those seen in mice
ith compromised steroid sulfatase function (i.e., reduced accu-
acy, slowed correct responses, increased omissions and de-
reased premature responding) (53). Although any suggestion of
mechanistic link between neurosteroid and acetylcholinergic/
ABAergic effects on attention is speculative, it may be pertinent
hat cholinergic neurons of the basal forebrain exhibit high
xpression of the GABAA 	3 subunit (54), the expression of
hich is reduced in the attentionally impaired 39,XO mouse (52).
t is also noteworthy that 1) 	4
2-type nicotinic receptors can
ontrol GABAergic transmission in the thalamus (55), 2) the gene
ncoding the 	4 nicotinic receptor subunit is associated with
DHD (56–58), 3) 	7-type nicotinic receptors may be found on
ABAergic interneurones (59), and 4) 	7 nicotinic receptor
nockout mice show attention deficits (increased omissions) in
he 5-CSRTT (60). In vivo microdialysis in COUMATE-treated and
9,XY*O mice, coupled with pharmacologic manipulations of the
cetylcholinergic and GABAergic systems, could be used to test
he idea that steroid sulfatase dysfunction causes attentional
eficits through perturbations in these systems.
Our data strengthen the case for STS as a candidate gene for
ttentional (dys)function in humans and suggest that it would be
orthwhile to investigate association between the gene and
DHD endophenotypes. Recent, as yet unreplicated, work does
ppear to show an association between STS variation and ADHD
61). Our data suggest that variation within STS may be particu-
ww.sobp.org/journallarly associated with the inattentive subtype of ADHD and
underlying differences in the structure or function of the
thalamocortical circuitry.
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